Vyondys 53

FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs
Xconomy
Wed, 01/22/20 - 06:41 pm
Sarepta Therapeutics
Vyondys 53
Duchenne Muscular Dystrophy
FDA
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
Biopharma Dive
Fri, 12/13/19 - 12:28 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Vyondys 53
Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug
Stat
Thu, 11/7/19 - 10:58 pm
Sarepta Therapeutics
Doug Ingram
FDA
Vyondys 53
Duchenne Muscular Dystrophy
The FDA and Sarepta: a window into the real world of drug regulation
Stat
Tue, 09/3/19 - 04:42 pm
FDA
regulatory
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Vyondys 53
Sarepta now needs flawless progress for gene therapy
Biopharma Dive
Tue, 08/20/19 - 10:58 pm
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
Vyondys 53
gene therapy
SRP-9001
Sarepta Duchenne drug rejected by FDA in surprise decision
Biopharma Dive
Mon, 08/19/19 - 11:48 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
complete response letter
Vyondys 53
Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings
Bloomberg
Mon, 08/19/19 - 10:28 am
Sarepta Therapeutics
analysts
Duchenne Muscular Dystrophy
Vyondys 53
Exondys 51